Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC

In time-to-event analyses controlling for thrombosis risk factors, the ALK rearrangement conferred a fourfold increase in VTE risk and a threefold increase in arterial thrombosis risk in NSCLC. These patients may benefit from pharmacologic thromboprophylaxis. READ ARTICLE

Journal of Thoracic Oncology DOI: 10.1016/j.jtho.2020.04.033

Authors: Hanny Al-Samkari, Orly Leiva, Ibiayi Dagogo-Jack, Alice Shaw, Jochen Lennerz, Anthony J Iafrate, Pavan K Bendapudi, Jean M Connors

Real-World OutcomesKirk SmithALK, anticoagulation, arterial thrombosis, lung cancer, venous thromboembolism